<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35545856</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1348-0421</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Microbiology and immunology</Title><ISOAbbreviation>Microbiol Immunol</ISOAbbreviation></Journal><ArticleTitle>Suitability of NIID-MDCK cells as a substrate for cell-based influenza vaccine development from the perspective of adventitious virus susceptibility.</ArticleTitle><Pagination><StartPage>361</StartPage><EndPage>370</EndPage><MedlinePgn>361-370</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1348-0421.12985</ELocationID><Abstract><AbstractText>The practical use of cell-based seasonal influenza vaccines is currently being considered in Japan. From the perspective of adventitious virus contamination, we assessed the suitability of NIID-MDCK cells (NIID-MDCK-Cs) as a safe substrate for the isolation of influenza viruses from clinical specimens. We first established a sensitive multiplex real-time PCR system to screen for 27 respiratory viruses and used it on 34 virus samples that were isolated by passaging influenza-positive clinical specimens in NIID-MDCK-Cs. Incidentally, the limit of detection (LOD) of the system was 100 or fewer genome copies per reaction. In addition to influenza viruses, human enterovirus 68 (HEV-D68) genomes were detected in two samples after two or three passages in NIID-MDCK-Cs. To further investigate the susceptibility of NIID-MDCK-Cs to adventitious viruses, eight common respiratory viruses were subjected to passages in NIID-MDCK-Cs. The genome copy numbers of seven viruses other than parainfluenza 3 decreased below the LOD by passage 4. By passaging in NIID-MDCK-Cs, the genome numbers of the input HEV-D68, 1 × 10<sup>8</sup> copies, declined to 10<sup>2</sup> at passage 3 and to under the LOD at passage 4, whereas those of the other six viruses were under the LOD by passage 3. These results implied that during the process of isolating influenza viruses with NIID-MDCK-Cs, contaminating viruses other than parainfluenza 3 can be efficiently removed by passages in NIID-MDCK-Cs. NIID-MDCK-Cs could be a safe substrate for isolating influenza viruses that can be used to develop cell-based influenza vaccine candidate viruses.</AbstractText><CopyrightInformation>© 2022 The Societies and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hamamoto</LastName><ForeName>Itsuki</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimasaki</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuta</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Yamagata Prefectural Institute of Public Health, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Ko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Virus Research Center, Sendai Medical Center, National Hospital Organization, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Hidekazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Virus Research Center, Sendai Medical Center, National Hospital Organization, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odagiri</LastName><ForeName>Takato</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tashiro</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nobusawa</LastName><ForeName>Eri</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0428-8606</Identifier><AffiliationInfo><Affiliation>Center for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>15fk0108009h0001</GrantID><Agency>Japan Agency for Medical Research and Development (AMED)</Agency><Country /></Grant><Grant><GrantID>16fk0108209j0002</GrantID><Agency>Japan Agency for Medical Research and Development (AMED)</Agency><Country /></Grant><Grant><GrantID>17fk0108309j00</GrantID><Agency>Japan Agency for Medical Research and Development (AMED)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Microbiol Immunol</MedlineTA><NlmUniqueID>7703966</NlmUniqueID><ISSNLinking>0385-5600</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061985" MajorTopicYN="N">Madin Darby Canine Kidney Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009975" MajorTopicYN="Y">Orthomyxoviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018184" MajorTopicYN="Y">Paramyxoviridae Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087506" MajorTopicYN="N">Vaccine Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014776" MajorTopicYN="N">Virus Cultivation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="Y">Viruses</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MDCK cells</Keyword><Keyword MajorTopicYN="N">adventitious virus</Keyword><Keyword MajorTopicYN="N">cell-based vaccine</Keyword><Keyword MajorTopicYN="N">influenza vaccine</Keyword><Keyword MajorTopicYN="N">real-time PCR</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>12</Day><Hour>2</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35545856</ArticleId><ArticleId IdType="doi">10.1111/1348-0421.12985</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9:e92153. https://doi.org/10.1371/journal.pone.0092153</Citation></Reference><Reference><Citation>Raymond DD, Stewart SM, Lee J, et al. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat Med. 2016;22:1465-69. https://www.nature.com/articles/nm.4223</Citation></Reference><Reference><Citation>Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl. Acad. Sci. USA. 2017;114:12578-83. https://www.pnas.org/cgi/doi/10.1073/pnas.1712377114</Citation></Reference><Reference><Citation>Wu NC, Zost SJ, Thompson AJ, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017;13:e1006682. https://doi.org/10.1371/journal.ppat.1006682</Citation></Reference><Reference><Citation>Barr IG, Donis RO, Katz JM, et al. Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: a step towards improved influenza vaccine effectiveness. NPJ Vaccines. 2018;3:44. https://doi.org/10.1038/s41541-018-0079-z</Citation></Reference><Reference><Citation>Seqirus. Seqirus is fist-to market with U.S. 2019/20 influenza vaccines. 2019. Accessed October 15, 2020. Available from: https://www.seqirus.com/news/seqirus-releases-first-shipment-for-2019-2020-season</Citation></Reference><Reference><Citation>Klein NP, Fireman B, Goddard K, et al. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS One. 2020;15:e0229279. https://doi.org/10.1371/journal.pone.0229279</Citation></Reference><Reference><Citation>WHO. Global influenza programme. Antigenic characterisation of seasonal influenza viruses isolated in vaccine-qualified cell line. WHO/HSE/PED/GIP/GISRS/2015.01. 2015. Available from: http://apps.who.int/iris/bitstream/10665/201995/1/WHO_HSE_PED_GIP_GISRS_2015.01.pdf?ua=1;2015</Citation></Reference><Reference><Citation>Stefanska I, Romanowska M, Donevski S, Gawryluk D, Brydak LB. Co-infections with influenza and other respiratory viruses. Adv Exp Med Biol. 2013;756:291-301. https://doi.org/10.1007/978-94-007-4549-0_36</Citation></Reference><Reference><Citation>Roth B, Mohr H, Enders M, Garten W, Gregersen JP. Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses. Vaccine. 2012;30:517-22. https://doi.org/10.1016/j.vaccine.2011.11.063</Citation></Reference><Reference><Citation>Gregersen JP. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine. 2008;26:3332-40. https://doi.org/10.1016/j.vaccine.2008.03.075</Citation></Reference><Reference><Citation>Farsang A, Kulcsár G. Extraneous agent detection in vaccines-a review of technical aspects. Biologicals. 2012;40:225-30. https://doi.org/10.1016/j.biologicals.2012.04.004</Citation></Reference><Reference><Citation>Gombold J, Karakasidis S, Niksa P, et al. Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products. Vaccine. 2014;32:2916-26. https://doi.org/10.1016/j.vaccine.2014.02.021</Citation></Reference><Reference><Citation>Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-94. https://genome.cshlp.org/content/6/10/986.long</Citation></Reference><Reference><Citation>Katano H, Kano M, Nakamura T, Kanno T, Asanuma H, Sata T. A novel real-time PCR system for simultaneous detection of human viruses in clinical samples from patients with uncertain diagnoses. J Med Virol. 83. 2011. 322-30. https://doi.org/10.1002/jmv.21962</Citation></Reference><Reference><Citation>Kaida A, Kubo H, Takakura K, et al. Associations between co-detected respiratory viruses in children with acute respiratory infections. Jpn J Infect Dis. 2014;67:469-75. https://www.jstage.jst.go.jp/article/yoken/67/6/67_67.469/_pdf/-char/en</Citation></Reference><Reference><Citation>Farsang A, Kulcsár G. Extraneous agent detection in vaccines-a review of technical aspects. Biologicals. 2012;40:225-30. https://doi.org/10.1016/j.biologicals.2012.04.004</Citation></Reference><Reference><Citation>Laassri M, Mee ET, Connaughton SM, et al. Detection of bovine viral diarrhoea virus nucleic acid, but not infectious virus, in bovine serum used for human vaccine manufacture. Biologicals. 2018;55:63-70. https://doi.org/10.1016/j.biologicals.2018.06.002</Citation></Reference><Reference><Citation>Malhotra B, Swamy MA, Reddy PV, Kumar N, Tiwari JK. Evaluation of custom multiplex real-time RT-PCR in comparison to fast-track diagnostics respiratory 21 pathogens kit for detection of multiple respiratory viruses. Virol J. 2016;13:19. https://doi.org/10.1186/s12985-016-0549-8</Citation></Reference><Reference><Citation>Barr IG, Rynehart C, Whitney P, Druce J. SARS-CoV-2 does not replicate in embryonated hen's eggs or in MDCK cell lines. Euro Surveill. 2020;25:2001122. https://doi.org/10.2807/1560-7917.ES.2020.25.25.2001122</Citation></Reference><Reference><Citation>Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020;117:7001-3. https://doi.org/10.1073/pnas.2002589117</Citation></Reference><Reference><Citation>Shirato K, Nao N, Katano H, et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis. 2020;73:304-7. https://doi.org/10.7883/yoken.JJID.2020.061</Citation></Reference><Reference><Citation>Nakauchi M, Yasui Y, Miyoshi T, et al. One-step real-time reverse transcription-PCR assays for detecting and subtyping pandemic influenza A/H1N1 2009, seasonal influenza A/H1N1, and seasonal influenza A/H3N2 viruses. J Virol Methods. 2011;141:156-62. https://doi.org/10.1016/j.jviromet.2010.10.018</Citation></Reference><Reference><Citation>Hayashi K. Role of tight junctions of polarized epithelial MDCK cells in the replication of herpes simplex virus type 1. J Med Virol. 1995;47:323-9. https://doi.org/10.1002/jmv.1890470406</Citation></Reference><Reference><Citation>Mizuta K, Abiko C, Aoki Y, et al. Seasonal patterns of respiratory syncytial virus, influenza A virus, human metapneumovirus, and parainfluenza virus type 3 infections on the basis of virus isolation data between 2004 and 2011 in Yamagata, Japan. Jpn J Infect Dis. 2013;66:140-5. https://doi.org/10.7883/yoken.66.140</Citation></Reference><Reference><Citation>Klein NP, Fireman B, Goddard K, et al. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS One. 2020;15:e0229279. https://doi.org/10.1371/journal.pone.0229279</Citation></Reference><Reference><Citation>Boikos C, Imran M, V Nguyen VH, Ducruet T, Sylvester GC, Mansi JA. Effectiveness of the cell-derived inactivated quadrivalent influenza vaccine in individuals at high risk of influenza complications in the 2018-2019 United States influenza season. Open Forum Infect Dis. 2021;Jul 8:ofab167. https://doi.org/10.1093/ofid/ofab167</Citation></Reference><Reference><Citation>Ding Yuan Oh1, Barr Ian G, Mosse JennyA, Laurie Karen L. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol. 2008;46:2189-94. https://doi.org/10.1128/JCM.00398-08.</Citation></Reference><Reference><Citation>Chambers BS, Li Y, Hodinka RL, Hensley SE. Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses. J Virol. 2014;18:10986-9. https://doi.org/10.1128/JVI.01077-14</Citation></Reference><Reference><Citation>Lin Y, Wharton SA, Whittaker L, et al. The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells. Influenza Other Respir Viruses. 2017;11:263-74. https://doi.org/10.1111/irv.12447</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>